MSD has reported that the randomised Phase III KEYNOTE-B96 trial of Keytruda (pembrolizumab) plus chemotherapy (paclitaxel), ...

Anticipates initiating the Company's Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for ...

BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

CytomX Therapeutics, Inc.’s CTMX share price has dipped by 9.45%, which has investors questioning if this is right time to ...

The ASX200 is set to open nearly three quarters of a percent lower today (-0.41%), echoing a mixed performance on Wall Street ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

CEO Frank Bedu-Addo highlighted the initiation of the VERSATILE 003 Phase 3 clinical trial of Versamune HPV plus pembrolizumab for first-line recurrence and/or metastatic HPV16-positive head and neck ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

Data presented at American Association for Cancer Research (AACR) Annual Meeting. In April 2025, Foghorn presented new preclinical data highlighting pipeline progress for potential first-in-class ...